Table 3: Changes from baseline in 6MWT endpoints at month 6.
| Endpoint |
Nintedanib |
Placebo |
| 6MWD |
- |
- |
| Number of patients |
55 |
52 |
| Mean (SE) change from baseline at month 6, m |
5 (11) |
‒13 (11) |
| Velocity during 6MWT |
- |
- |
| Number of patients |
46 |
46 |
| Mean (SD) change from baseline at month 6, m/min |
1.2 (12.8) |
−2.1 (13.7) |
| Oxygen saturation nadir during 6MWT |
- |
- |
| Number of patients |
46 |
46 |
| Mean (SD) change from baseline at month 6, % |
1.2 (5.4) |
1.4 (3.1) |
| Resting SpO2 minus lowest SpO2 during 6MWT (delta desaturation) |
- |
- |
| Number of patients |
46 |
46 |
| Mean (SD) change from baseline at month 6, % |
1.1 (5.3) |
1.4 (3.2) |
6MWD, six-minute walk distance; 6MWT, six-minute walk test; SpO2, oxygen saturation.